News

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need. Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investors. Existing investors i&i Biotech Fund I SCSp, HIL-INVENT and Brandenburg Kapital also participated in the round.

HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases.

KyDo secures €4.45 million seed funding to develop a covalent-allosteric drug discovery platform and to advance its frontrunner inhibitors towards IND-enabling studies. The financing round is led by I&I Bio, with a significant investment from KHAN-II, and investments from VORNvc and TU capital. KyDo’s lead program consists of novel covalent-allosteric inhibitors with potential to become first-in-class oncology drugs.

Interview with Pavlína Koutecká, Scientific Analyst at i&i Biotech Fund. Among other topics, she discusses the opportunities presented by the use of artificial intelligence in Life Sciences, the associated risks, and why we should not fear that artificial intelligence will one day replace scientists.

Read the interview with Nicolas Beuzen, the new Investment Advisor at i&i Biotech Fund. In addition to other topics, the interview covers his goals and visions for joining i&i Bio, the reasons behind his decision to accept the job offer, and how specific activities like off-road motorcycling and Battodo are beneficial to his work.

CasInvent Pharma, a university spin-off focused on developing anti-cancer compounds, has successfully closed the Pre-Series A funding round, raising a total of € 1.6 million from both existing and two new investors. The syndicate includes i&i Biotech Fund (i&i Bio), KHAN Technology Transfer Fund I (KHAN-I), i&i Prague, the Holeček Family Foundation, and BIOINVESTIMED a. s.. The financing will boost the development of innovative casein kinase 1 (CK1) inhibitors with the potential to treat conditions like acute myeloid leukaemia, pancreatic cancer, and certain types of breast cancer.

i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed round. Funds will be used to accelerate a new generation of T cell therapies against solid tumors towards the clinic.

Vasa, a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular and metabolic aging, yesterday announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to initiate a Phase 1 first-in-human clinical trial.

iQure, a company focused on the development of novel therapies based on Polish research for neurological conditions, has completed its latest round of funding. The company has raised $4M to progress with a Phase 1 clinical trial for its lead asset iQ-007, a novel therapeutic candidate to treat epilepsy and other neurodegenerative conditions.

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many in partnership with pharmaceutical companies.